Clinical pharmacology of fentanyl buccal tablet for the treatment of breakthrough pain

Darwish, Mona; Messina, John

doi:10.1586/17512433.1.1.39

Cited by 4 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral transmucosal fentanyl citrate (OTFC) (introduced 1998) or Fentanyl buccal tablets (FBT) (introduced 2006) may be used for management of breakthrough pain. 24 Transdermal buprenorphine may also be used for management of cancer pain with oral morphine used for breakthrough pain.…”

Section: Opioids In Management Of Chronic Cancer Patientsmentioning

confidence: 99%

Pain Management in Patients with Head and Neck Carcinoma

Ghei¹,

Khot²,

Hathiram³

et al. 2010

An International Journal of Otorhinolaryngology Clinics

View full text Add to dashboard Cite

Pain is one of the feared effects of advancing cancer and can affect a vast majority of head and neck cancer (HNC) patients. HNC's have a devastating impact on patient's lives as both disease and treatment can affect the ability to speak, swallow and breathe due to involvement of the aerodigestive tract. The etiology of pain in this subgroup of patients could be as a result of direct tumor progression, nerve root compression or as a result of the treatment modalities including surgery radiotherapy and chemotherapy. Pain experienced could be nociceptive or neuropathic. A thorough initial and ongoing assessment of the patient is essential for diagnosis and planning the treatment bearing in mind its modification during treatment. Treatment involves a comprehensive approach which is centred around systematic pharmacotherapy, and supplemented by a range of therapeutic interventions and physical and behavioral approaches. In this article we discuss the incidence, etiology, assessment and treatment of this challenging problem using current modalities.

show abstract

Section: Opioids In Management Of Chronic Cancer Patientsmentioning

confidence: 99%

Pain Management in Patients with Head and Neck Carcinoma

Ghei¹,

Khot²,

Hathiram³

et al. 2010

An International Journal of Otorhinolaryngology Clinics

View full text Add to dashboard Cite

show abstract

Breakthrough pain and rapid-onset opioids in patients with cancer pain: a narrative review

Yeo¹

2024

JYMS

View full text Add to dashboard Cite

Breakthrough pain is transitory pain that occurs despite the use of opioids for background pain control. Breakthrough pain occurs in 40% to 80% of patients with cancer pain. Despite effective analgesic therapy, patients and their caregivers often feel that their pain is not sufficiently controlled. Therefore, an improved understanding of breakthrough pain and its management is essential for all physicians caring for patients with cancer. This article reviews the definition, clinical manifestations, accurate diagnostic strategies, and optimal treatment options for breakthrough pain in patients with cancer. This review focuses on the efficacy and safety of rapid-onset opioids, which are the primary rescue drugs for breakthrough pain.

show abstract